EUVIMEDEUVIMED entdecken
Crossref

Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

JAMA · 12.11.2026 · e2623165

DOI: 10.1001/jama.2026.23165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, online erschienen am 12.11.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma. JAMA, e2623165. https://doi.org/10.1001/jama.2026.23165

Vancouver

Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma. JAMA. 2026:e2623165. doi:10.1001/jama.2026.23165

BibTeX
@article{euvimed2026,
  title = {Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma},
  journal = {JAMA},
  year = {2026},
  pages = {e2623165},
  doi = {10.1001/jama.2026.23165}
}
Kostenlos starten →